1. Home
  2. VERU vs LSE Comparison

VERU vs LSE Comparison

Compare VERU & LSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERU
  • LSE
  • Stock Information
  • Founded
  • VERU 1971
  • LSE 2007
  • Country
  • VERU United States
  • LSE China
  • Employees
  • VERU N/A
  • LSE N/A
  • Industry
  • VERU Biotechnology: Pharmaceutical Preparations
  • LSE Metal Fabrications
  • Sector
  • VERU Health Care
  • LSE Industrials
  • Exchange
  • VERU Nasdaq
  • LSE Nasdaq
  • Market Cap
  • VERU 88.4M
  • LSE 86.8M
  • IPO Year
  • VERU 1990
  • LSE 2024
  • Fundamental
  • Price
  • VERU $0.61
  • LSE $5.10
  • Analyst Decision
  • VERU Strong Buy
  • LSE
  • Analyst Count
  • VERU 2
  • LSE 0
  • Target Price
  • VERU $4.00
  • LSE N/A
  • AVG Volume (30 Days)
  • VERU 4.2M
  • LSE 11.1K
  • Earning Date
  • VERU 08-07-2025
  • LSE 01-01-0001
  • Dividend Yield
  • VERU N/A
  • LSE N/A
  • EPS Growth
  • VERU N/A
  • LSE N/A
  • EPS
  • VERU N/A
  • LSE 0.52
  • Revenue
  • VERU $16,886,419.00
  • LSE $69,073,374.00
  • Revenue This Year
  • VERU N/A
  • LSE N/A
  • Revenue Next Year
  • VERU N/A
  • LSE N/A
  • P/E Ratio
  • VERU N/A
  • LSE $9.76
  • Revenue Growth
  • VERU 134.43
  • LSE N/A
  • 52 Week Low
  • VERU $0.45
  • LSE $3.76
  • 52 Week High
  • VERU $1.42
  • LSE $14.99
  • Technical
  • Relative Strength Index (RSI)
  • VERU 55.87
  • LSE N/A
  • Support Level
  • VERU $0.61
  • LSE N/A
  • Resistance Level
  • VERU $0.74
  • LSE N/A
  • Average True Range (ATR)
  • VERU 0.06
  • LSE 0.00
  • MACD
  • VERU 0.01
  • LSE 0.00
  • Stochastic Oscillator
  • VERU 50.42
  • LSE 0.00

About VERU Veru Inc.

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

About LSE Leishen Energy Holding Co. Ltd. Ordinary Shares

Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment; oil and gas engineering technical services; new energy production and operation; and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment which supplies various equipments, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.

Share on Social Networks: